The stock of Gilead Sciences Inc. (NASDAQ:GILD) decreased by -$0.15 on Monday to finish at $79.85, down -0.19 percent. The last five days have seen an average of 4,187,920 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$6.00. The average number of shares traded over the last 20 days was 6,079,360, while the average volume over the last 50 days totaled 5,840,526.
GILD stock appreciated 3.45% since last month. On 08/01/23, the company’s shares reached a one-month low of $75.10. The stock touched a high of $89.74 on 01/06/23, after rallying from a low of $61.44 in 52 weeks. The price of GILD stock has declined by -6.99% or -$6.00 this year, reaching a new high 3 times. Still, the stock price is down -11.02% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GILD stock investors should be aware that Gilead Sciences Inc. (GILD) stock had its last reported insider trading activity 26 days ago on Jul 20. On Jul 20, Chief Financial Officer Dickinson Andrew D sold 5,000 shares at $80.00 each. This transaction resulted in the insider making $400,000. On Jun 28, GILEAD SCIENCES, INC. added 1,010,000 shares at a price of US$19.26. After the transaction, the insider now owns 14,823,029 shares. 10% Owner GILEAD SCIENCES, INC. had earlier bought 2,930,870 shares on Jun 27 for $3.75 a share. The transaction was completed for $10,990,762.
Valuation Metrics
Gilead Sciences Inc. (GILD) has a trailing price-to-earnings (P/E) ratio of 18.37. Beta for the stock is 0.38. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.63, the price-to-book (PB) ratio of 4.71, and the price-to-cash flow ratio of 11.15.
Company paid $0.75 per share in dividends, remained unchanged from $0.75 last year.
Financial Health
For the three months ended June 29, Gilead Sciences Inc.’s quick ratio was 0.90, while its current ratio was 1.00, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.00, and the total debt to equity ratio is 1.19. As far as profitability goes, gross margin for the trailing twelve months is 79.40% percent. Gilead Sciences Inc.’s EBITDA margin for the year ended June 29 was 47.48%, whereas its operating margin stood at 30.90% for the same period. Based on annual data, it had gross profit of $21.62 billion and revenue of $27.28 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GILD’s return on assets (ROA) during the last 12 months has been 8.80%. There was a 13.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 26.00%.
Earnings Surprise
According to Gilead Sciences Inc.’s quarterly financial report for the quarter that ended June 29, it had $21.21 billion in total debt versus $963.0 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.6 billion, while revenues rose by 5.14% to $6.35 billion. It was predicted that Gilead Sciences Inc.’s quarterly earnings would be $1.34, but it ended up being $1.64, beating the consensus by -18.30%. EBITDA was $2.35 billion for the quarter. At the end of Gilead Sciences Inc.’s most recent quarter ended June 29, its liabilities totaled 41.24 billion, while its total debt was $25.25 billion. Equity owned by shareholders amounts to $1.25 billion.
Technical Picture
Here’s a quick look at Gilead Sciences Inc.’s (GILD) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 62.79%, suggesting the stock is Neutral, with a 24.13% historical volatility rate.
The stochastic %K and %D were 76.62% and 78.32% respectively, while the average true range (ATR) was 1.54. Based on the 14-day stochastic reading of 75.04%, the RSI (14) reading is 59.43%. On the 9-day MACD Oscillator, the stock is at 0.99, and the 14-day reading is at 1.88.
Analyst Ratings
In a note to investors, Barclays maintained its an Equal weight rating on Gilead Sciences Inc. (NASDAQ: GILD). However, the firm raised their price target to $80, indicating a possible increase of 1.42% in the stock price. Analysts have assigned Gilead Sciences Inc. (GILD) an Overweight rating. GILD is a stock that is recommended for selling by 0 brokerage firms, while 16 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 13 others recommend it as a buy.
What is GILD’s price target for the next 12 months?
The current consensus forecast for the stock is between $80.00 and $116.00, with a median target price of $90.00. In analyzing these forecasts, the average price target given by analysts for Gilead Sciences Inc. (GILD) is $91.23.
